Evidence map›Paper›PMID 42292133›Full record

ArticleInternational journal of microbiology2026

Conocarpan and Eupomatenoid-6 as Natural Prototypes for Antituberculosis Compounds.

Lincoln Luís Silva, Anderson Valdiney Gomes Ramos, Debora Cristina Baldoqui, Nathally Claudiane de Souza Santos, Vera Lucia Dias Siqueira, Katiany Rizzieri Caleffi-Ferracioli, Rosilene Fressatti Cardoso, Rosi Zanoni da Silva, Regiane Bertin de Lima Scodro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lincoln Luís SilvaDepartment of Pharmacy, State University of Midwest Paraná, Guarapuava, Brazil.ORCID https://orcid.org/0000-0001-8445-0743
Anderson Valdiney Gomes RamosDepartment of Chemistry, State University of Maringá, Maringá, Brazil, uem.br.ORCID https://orcid.org/0000-0001-9863-018X
Debora Cristina BaldoquiDepartment of Chemistry, State University of Maringá, Maringá, Brazil, uem.br.ORCID https://orcid.org/0000-0002-5824-8573
Nathally Claudiane de Souza SantosDepartment of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil, uem.br.
Vera Lucia Dias SiqueiraDepartment of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil, uem.br.ORCID https://orcid.org/0000-0001-7973-4098
Katiany Rizzieri Caleffi-FerracioliDepartment of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil, uem.br.ORCID https://orcid.org/0000-0003-0345-1600
Rosilene Fressatti CardosoDepartment of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil, uem.br.ORCID https://orcid.org/0000-0001-6228-4780
Rosi Zanoni da SilvaDepartment of Pharmaceutical Sciences, State University of Ponta Grossa, Ponta Grossa, Brazil, uepg.br.ORCID https://orcid.org/0000-0001-6734-9520
Regiane Bertin de Lima ScodroDepartment of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Brazil, uem.br.ORCID https://orcid.org/0000-0002-9129-2445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Tuberculosis (TB) is caused by Experimental Procedure: Compounds were obtained through high-performance liquid chromatography. The in vitro activities were determined by the resazurin microtiter assay, and their combinatory effect with anti-TB and antiretroviral were determined by the resazurin drug combination microtiter assay against Key Results: Compounds (1) and (2) showed activity against Conclusions and Implications: The synergistic interaction between conocarpan and rifampicin, coupled with the lack of antagonism with antiretroviral drugs, suggests that these neolignans are promising candidates for further development in the treatment of drug-resistant TB and TB/HIV coinfection.

Indexed as

antitubercular agentscytotoxicityMycobacterium tuberculosisneolignansPiper

Identifiers

PMID42292133
PMCPMC13254484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.